Thermo Fisher Scientific has increased its gene editing technology offering by licensing CRISPR/Cas9 technologies from the Broad Institute and ERS Genomics. Thermo Fisher will now be able to offer its biopharma customers several genome editing offerings through the in-license deals. “Genome editing has unlocked the door for researchers to begin understanding gene function, which is fundamental in unraveling and outlining basic biological processes and disease pathways,” said Helge Bastian, vice president and general manager of Synthetic Biology at Thermo Fisher…